Baxter has received positive recommendations for its avian flu (H5N1) pandemic vaccine CELVAPAN for use in the European Union, it has revealed.
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) has issued its verdict on the product ahead of the firm submitting its licence for the vaccine - which could authorise its use in the event of the World Health Organization declaring a pandemic.
This recommendation comes after a clinical trial found that vaccines for two different H5N1 virus strains were well-tolerated and generated an immune response in candidates.
Hartmut Ehrlich, vice-president of bioscience global research and development at the firm, commented: "This is another step towards our goal of supplying a safe and effective vaccine to protect the population against a possible influenza pandemic."
In other Baxter news, the firm's board of directors declared a quarterly dividend of $0.29 (17p) per common share last week, marking an increase over the previous quarterly rate of $0.26 per share.See all the latest jobs in Pharmaceutical